US EditionPublished • loading... • Updated
Astrazeneca Profit Jumps as Cancer Drug Sales Grow
AstraZeneca's 40% profit rise in 2025 was driven by cancer drug sales and growth in the US and China markets amid $50 billion planned investments through 2030.
- On Tuesday, AstraZeneca reported pre-tax profits of 12.4 billion dollars for 2025, a 40% increase, as shares edged 1% higher after starting trading on the NYSE earlier this month.
- Expansion into the United States and China underpins AstraZeneca's growth, driven by demand for cancer medicines and investment in weight-loss and diabetes treatments, including an 18.5 billion dollar deal.
- Financial details show operating profits rose 36% to 13.74 billion dollars and revenues lifted 8% to 58.74 billion dollars, though sales of Farxiga grew 2%.
- It said revenues are set to rise by a mid‑to‑high single‑digit percentage in 2026 and underlying earnings per share guidance for 2026 expects a low double‑digit rise.
- The company plans around 50 billion dollars in investment by 2030 and reaffirmed an 80 billion dollars sales target by 2030, focusing on the US and China, the primary markets, the CEO said.
Insights by Ground AI
20 Articles
20 Articles
ABC FOX Montana+11 Reposted by 11 other sources
AstraZeneca profit jumps as cancer drug sales grow
British pharmaceutical giant AstraZeneca said Tuesday that its net profit jumped 45 percent last year on strong sales of cancer drugs, as it expands its reach in the United States and China.
·Missoula, United States
Read Full Article
British pharmaceutical company AstraZeneca reported a net profit of $10.2 billion (€8.6 billion) last year, up 45 percent from the previous year, driven by sales of cancer drugs and a strengthening of its business in the United States and China.
The profits of the fourth quarter grew by 55.3%, to 1,957 million euros ...
·Luxembourg City, Luxembourg
Read Full Article
Coverage Details
Total News Sources20
Leaning Left4Leaning Right4Center4Last UpdatedBias Distribution34% Left, 33% Center, 33% Right
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
34% Left
L 34%
C 33%
R 33%
Factuality
To view factuality data please Upgrade to Premium
